Health Canada approves emergency use for Pfizer, BioNTech's COVID-19 vaccine

By The Science Advisory Board staff writers

December 9, 2020 -- Health Canada has granted authorization under an interim order for the emergency use of Pfizer-BioNTech's messenger RNA COVID-19 vaccine, BNT162b2.

The distribution of the vaccine in Canada will be prioritized according to the populations identified by the National Advisory Committee on Immunizations. BioNTech will hold the regulatory approval in Canada, while Pfizer Canada will have commercialization rights.

Health Canada's decision is based on data filed through a rolling submission regulatory pathway and included data from phase II/III clinical trials which began in July 2020 and has enrolled approximately 44,000 people globally.

Pfizer Canada and BioNTech will supply the Canadian government a minimum of 20 million doses and up to 76 million doses of the vaccine through 2021.

Copyright © 2020

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.